In particular, serum MIF is highly elevated in the potentially curable early stages of gastric cancer thus warranting further studies to validate this candidate biomarker as a blood test for gastric cancer, either on its own or as part of a panel of biomarkers. Here, MIF is linked to gastric cancer.